Restrictions in use of Xeljanz while EMA reviews risk of blood clots in lungs

View source ↗

Summary

The EMA announced restrictions on the use of Xeljanz (tofacitinib) while it reviews the risk of blood clots in the lungs, indicating potential safety concerns a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• XELJANZ (tofacitinib)